Evidence map›Paper›PMID 39443000›Full record

ReviewClinics in chest medicine2024

Cellular Mechanisms of Lung Injury: Current Perspectives.

Jamie E Meegan, Alicia N Rizzo, Eric P Schmidt, Julie A Bastarache

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinics in chest medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. From development to regeneration: the endothelial interface in lung injury and repair.American journal of physiology. Lung cellular and molecular physiology · 2025
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jamie E MeeganDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Alicia N RizzoDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Bulfinch 148, Boston, MA 02114, USA.
Eric P SchmidtDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Bulfinch 148, Boston, MA 02114, USA.
Julie A BastaracheDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address: julie.bastarache@vumc.org.

Funding

Applying Innovative Lung Mapping Strategies to Understand Alveolar Capillary Barrier Permeability in ARDSR35HL150783 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Julie A. Bastarache · 2020 to 2026
$4.6M
The Sepsis ClinicAl Resource And Biorepository (SCARAB) ProjectR33GM144915 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BASTARACHE, JULIE A., WARE, LORRAINE B · 2024 to 2025
$1.5M
Cell-free hemoglobin-oxidized LDL-LOX-1 axis and microvascular hyperpermeability during sepsisR00HL166865 · NHLBI · UNIVERSITY OF SOUTH ALABAMA · PI Jamie E Meegan · 2024 to 2026
$747k
The Sepsis ClinicAl Resource And Biorepository (SCARAB) ProjectR21GM144915 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BASTARACHE, JULIE ANNE, WARE, LORRAINE B · 2022 to 2023
$474k
Epithelial glycocalyx degradation mediates surfactant dysfunction in acute respiratory distress syndromeF32HL162230 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI RIZZO, ALICIA N · 2022 to 2023
$121k
NHLBI NIH HHS F32 HL162230NHLBI NIH HHS L30 HL159703NHLBI NIH HHS R00 HL166865NHLBI NIH HHS R35 HL150783NIGMS NIH HHS R21 GM144915NIGMS NIH HHS R33 GM144915
6 · The paper itself

Abstract

The alveolar-capillary barrier includes microvascular endothelial and alveolar epithelial cells and their matrices, and its disruption is a critical driver of lung injury during development of acute respiratory distress syndrome. In this review, we provide an overview of the structure and function of the alveolar-capillary barrier during health and highlight several important signaling mechanisms that underlie endothelial and epithelial injury during critical illness, emphasizing areas with potential for development of therapeutic strategies targeting alveolar-capillary leak. We also emphasize the importance of biomarker and preclinical studies in developing novel therapies and highlight important areas warranting future investigation.

Indexed as

Respiratory Distress SyndromeAcute Lung InjuryAlveolar Epithelial CellsEndothelial CellsHumansLung InjuryPulmonary AlveoliSignal TransductionAlveolar epithelial type 1cellsAlveolar epithelial type 2cellsAlveolar epitheliumGlycocalyxLung microvascular endotheliumPermeability

Identifiers

PMID39443000
PMCPMC11499619

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.